RNA Aptamers that Specifically Bind the Soluble Interleukin-6 Receptor

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention discloses RNA aptamers that specifically bind to the human soluble interleukin-6 receptor (sIL-6R). These RNA aptamers can serve as both diagnostic and therapeutic agents for diseases involving the IL-6 pathway, such as inflammatory conditions, cancers, and infectious diseases. Compared to antibodies, aptamers offer higher stability, lower immunogenicity, and potentially fewer side effects.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of diagnostic kits to detect abnormal levels of sIL-6R in blood for disease monitoring and early detection.
• Creation of new therapeutic agents to treat autoimmune diseases like rheumatoid arthritis, Crohn's disease, and multiple sclerosis by neutralizing sIL-6R activity.
• Use in targeted cancer therapies, particularly in cancers with an IL-6/sIL-6R signaling component, such as breast cancer and multiple myeloma.
• Treatment or prevention of systemic inflammatory conditions and sepsis through aptamer-mediated inhibition of the relevant receptors.
• Use as carriers to deliver drugs, peptides, or imaging agents selectively to cells that express sIL-6R or IL-6R, expanding utility to precision medicine and molecular imaging.

BenefitsContent extracted from patent full text and abstract with AI.

• High specificity and affinity for human sIL-6R, enabling targeted intervention.
• Potentially lower immunogenicity than monoclonal antibodies, translating to fewer adverse effects.
• Easy and cost-effective synthesis and scalable manufacturing of aptamers.
• Improved stability and storability compared to protein therapeutics (like antibodies).
• Flexibility to be chemically modified for enhanced stability, cellular uptake, or in vivo persistence.
• Potential application in both diagnostics and therapeutics, including targeted drug delivery.
• May address needs in multiple diseases where IL-6/sIL-6R plays a pathological role.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to aptamers specifically binding to a target molecule. The aim of the invention is to prepare diagnostic and/or therapeutic agents for use in the recognition and/or prevention or treatment of inflammatory processes, of cancerous diseases and of infections. To achieve this aim, the invention provides RNA aptamers that specifically bind to the human soluble interleukin-6 receptor (sIL-6R).